These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 24145678

  • 41. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aksan A, Işık H, Radeke HH, Dignass A, Stein J.
    Aliment Pharmacol Ther; 2017 May; 45(10):1303-1318. PubMed ID: 28326596
    [Abstract] [Full Text] [Related]

  • 42. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
    Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A, AEGIS Study Group.
    Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
    [Abstract] [Full Text] [Related]

  • 43. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
    Iqbal T, Stein J, Sharma N, Kulnigg-Dabsch S, Vel S, Gasche C.
    Dig Dis Sci; 2015 May; 60(5):1375-81. PubMed ID: 25501922
    [Abstract] [Full Text] [Related]

  • 44. Iron (III) isomaltoside 1000.
    Mace TA, Syed A, Bhandari S.
    Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
    [Abstract] [Full Text] [Related]

  • 45. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
    Shi L, Zhao Y, Rao A.
    Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
    [Abstract] [Full Text] [Related]

  • 46. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [Abstract] [Full Text] [Related]

  • 47. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
    Johansson PI, Rasmussen AS, Thomsen LL.
    Vox Sang; 2015 Oct; 109(3):257-66. PubMed ID: 25900643
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial.
    Hansen R, Sommer VM, Pinborg A, Krebs L, Thomsen LL, Moos T, Holm C.
    Arch Gynecol Obstet; 2023 Oct; 308(4):1165-1173. PubMed ID: 36107229
    [Abstract] [Full Text] [Related]

  • 53. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma.
    Ng O, Keeler B, Simpson JA, Madhusudan S, Brookes M, Acheson A.
    Nutr Cancer; 2018 Oct; 70(7):1106-1117. PubMed ID: 30198775
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.
    Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J.
    Trials; 2015 Jan 14; 16():5. PubMed ID: 25588587
    [Abstract] [Full Text] [Related]

  • 58. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
    Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A.
    Am J Kidney Dis; 2016 Nov 14; 68(5):677-690. PubMed ID: 27321965
    [Abstract] [Full Text] [Related]

  • 59. Treatment with Noripurum EV® is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.
    Venturieri MO, Komati JTS, Lopes LHC, Sdepanian VL.
    Scand J Gastroenterol; 2019 Feb 14; 54(2):198-204. PubMed ID: 30782036
    [Abstract] [Full Text] [Related]

  • 60. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study.
    Mulder MB, van den Hoek HL, Birnie E, van Tilburg AJP, Westerman EM.
    Br J Clin Pharmacol; 2019 Feb 14; 85(2):385-392. PubMed ID: 30393904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.